The Form 4 filing lists EcoR1 Capital, LLC as a director and 10% owner. This report of changes in insider stock ownership was filed on November 18, 2026. It covers purchases from November 16 through November 18.
AnaptysBio is listed in the healthcare sector and biotechnology industry. The report covers one reporting owner and three purchase transactions within a single filing.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-18 |
| Buy/Sell | buy |
| Transaction Count | 3 |
| Shares Transacted | 374,580 |
| Price | $45.98 |
| Total Transaction Value | $17,224,592.78 |
| Insider | |
| Ticker Symbol | ANAB |
| Company | ANAPTYSBIO, INC |
| Insider Name | EcoR1 Capital, LLC |
| Insider Title | Director, 10% Owner |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 8,254,674 |
| Position Size Change | 4.54% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were purchases of ANAB shares, reported with transaction code P. The available information identifies three purchases but does not give separate share counts for each trade.
What was the average price of the transaction?
The average purchase price was $45.98 per share, rounded to the nearest cent. This average covers the shares bought across all three transactions. Separate prices for each trade were not available.
How did this transaction affect the insider's holdings?
EcoR1 Capital, LLC bought 374,580 shares and reported 8,254,674 shares owned afterward. The shares bought made up 4.54% of that reported total.
What's the total transaction value?
The total value was $17,224,592.78 across the three purchases. This amount covers all 374,580 shares bought during the reported period.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement. Filing footnote text was not available for this report, so any further terms or explanations in those notes remain unknown.
Source: SEC Form 4.
For research purposes only; not investment advice.